Clinical Implications of New Drinking Water Regulation for “Forever Chemicals”
JAMA · 2024
DOI: 10.1001/jama.2024.12705 ↗Kurz gefasst
Editorial in der Zeitschrift JAMA, 2024. Verfasst von Rachel Criswell und 2 weiteren Autor:innen. Beteiligte Einrichtung: Skowhegan Family Medicine, Redington-Fairview General Hospital, Skowhegan, Maine. Hauptthemen laut MEDLINE: Drinking Water, Water Pollutants, Chemical, Fluorocarbons. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 7 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIAMS NIH HHS, NIEHS NIH HHS.
Abstract (Originalsprache)
This Viewpoint describes new maximum contaminant levels set by the Environmental Protection Agency for specific perfluoroalkyl and polyfluoroalkyl substances (PFASs) and discusses the role clinicians can play in addressing their patients’ PFAS health concerns.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Skowhegan Family Medicine, Redington-Fairview General Hospital, Skowhegan, Maine.
- Department of Epidemiology, Geisel School of Medicine, Dartmouth College, Lebanon, New Hampshire.
- Center for Interdisciplinary and Population Health Research, MaineHealth Institute for Research, Westbrook.
- Pediatric Endocrinology and Diabetes, Maine Medical Center, Portland.
- School of Public Health, West Virginia University, Morgantown.
Förderung
- NIAMS NIH HHS
- NIEHS NIH HHS
Zitieren
APA
Criswell, R., Fleisch, A. F., & Ducatman, A. (2024). Clinical Implications of New Drinking Water Regulation for “Forever Chemicals”. JAMA. https://doi.org/10.1001/jama.2024.12705
Vancouver
Criswell R, Fleisch AF, Ducatman A. Clinical Implications of New Drinking Water Regulation for “Forever Chemicals”. JAMA. 2024. doi:10.1001/jama.2024.12705
BibTeX
@article{Criswell2024,
author = {Criswell, Rachel and Fleisch, Abby F and Ducatman, Alan},
title = {Clinical Implications of New Drinking Water Regulation for “Forever Chemicals”},
journal = {JAMA},
year = {2024},
doi = {10.1001/jama.2024.12705}
}
EUVIMED